Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;37(4):938-941.
doi: 10.1038/s41375-023-01831-1. Epub 2023 Feb 1.

Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

Constance Baer #  1 , Sandra Huber #  2 , Stephan Hutter  2 , Manja Meggendorfer  2 , Niroshan Nadarajah  2 , Wencke Walter  2 , Uwe Platzbecker  3 , Katharina S Götze  4 , Wolfgang Kern  2 , Torsten Haferlach  2 , Gregor Hoermann  2 , Claudia Haferlach  2
Affiliations

Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

Constance Baer et al. Leukemia. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CH, WK and TH declare part ownership of MLL Munich Leukemia Laboratory. CB, SH, StH, MM, NN, WW and GH are employed by MLL Munich Leukemia Laboratory. UP has received honoraria and research support by BMS, Janssen, Novartis. KSG has received honoraria from BMS, Abbvie, Pfizer and JAZZ pharmaceuticals.

Figures

Fig. 1
Fig. 1. Validation of the IPSS-M.
A Frequencies of IPSS-M categories and specific parameters within our MDS validation cohort (n = 626) compared to the data published by Bernard et al. B Kaplan–Meier plots for MDS patients classified according to the IPSS-M for overall survival (OS), leukemia free survival (LFS) and leukemic transformation (LT).
Fig. 2
Fig. 2. Comparison of IPSS-R and IPSS-M.
A Changes in MDS risk categories of MDS patients (n = 452) according IPSS-R and IPSS-M. B Model discrimination as measured by Harrell’s c-index of the IPSS-R or IPSS-M across the different end points (OS overall survival, LFS leukemia-free survival, LT leukemic transformation).
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. doi: 10.1182/blood-2012-03-420489. - DOI - PMC - PubMed
    1. Cazzola M, la Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021–2034. doi: 10.1182/blood-2013-09-381665. - DOI - PMC - PubMed
    1. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27. doi: 10.1182/blood-2013-08-518886. - DOI - PMC - PubMed